A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Study Identifier
M12-671
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Endometriosis
  • Study Drug
  • Elagolix
  • Phase
    Phase 3
    Sex
    Female
    Age
    18 - 49 Years

    Protocol Summary

    A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.

    Study Locations

    No locations found.